Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/10/26
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.The Motley Fool • 09/09/26
How Novartis And Ionis' High-Profile Failure Reverberated Through BiopharmaInvestors Business Daily • 09/08/26
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionBenzinga • 09/08/26
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock DownZacks Investment Research • 09/07/26
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study GoalZacks Investment Research • 09/07/26
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)Business Wire • 09/04/26
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease TranscriptSeeking Alpha • 09/04/26
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patientsBusiness Wire • 09/03/26
Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?Zacks Investment Research • 08/28/26
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026Business Wire • 08/20/26
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS LawBusiness Wire • 08/08/26
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?The Motley Fool • 08/03/26